Lord’s Mark Biotech, a subsidiary of Lord’s Mark Industries, has introduced Tinefcon, a patented medicine for treating Psoriasis. Lord’s Mark Biotech has signed an exclusivity agreement with INVEX Health Pvt Ltd for a patented product developed by Piramal life sciences in India, Tinefcon, which is being launched as a total solution for Psoriasis in four forms, priced between Rs. 799 – Rs. 3900.
Lord’s Mark Biotech, the exclusive distributor for Tinefcon, is utilizing a scientific sales force and a robust social media campaign to promote the product’s Psoriasis solution, and will also offer it on internet marketplaces for patient recommendation.
Lord’s Mark Biotech has invested Rs. 20 Crores in India’s Tinefcon market and distribution, aiming for revenue of Rs.100 crores by 2025. Commenting on the launch, Mr. Sachidanand Upadhyay, MD, Lord’s Mark Biotech, said, “We’re looking forward to making Tinefcon a major success in India and reaching out to a wider patient base as we expand our presence.’’
